科兴制药: 第二届监事会第二十四次会议决议公告

Meeting Overview - The second meeting of the second supervisory board of the company was held on August 14, 2025, with all three supervisors present [1]. Resolutions Passed Use of Raised Funds - The supervisory board approved the proposal to provide interest-free loans from raised funds to the wholly-owned subsidiary Shenzhen Kexing Pharmaceutical for project implementation, aligning with the fundraising plan and benefiting project execution [1]. Foreign Exchange Derivative Transactions - The board approved the proposal for the company and its subsidiaries to engage in foreign exchange derivative transactions, with a limit of 75 million RMB or equivalent foreign currency, to mitigate foreign exchange risk and enhance financial stability [2]. Related Party Transaction Agreement - The board approved the signing of a supplementary agreement for related party transactions, confirming compliance with regulations and ensuring no adverse effects on the company's financial status or shareholder interests [2]. Issuance of Technology Innovation Bonds - The board approved the proposal for the company to issue technology innovation bonds, affirming that it aligns with the overall interests of the company and shareholders [3].